Limits...
An innovative intervention for the treatment of cognitive impairment-Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer's disease and mild cognitive impairment: an open-label study.

Guerriero F, Botarelli E, Mele G, Polo L, Zoncu D, Renati P, Sgarlata C, Rollone M, Ricevuti G, Maurizi N, Francis M, Rondanelli M, Perna S, Guido D, Mannu P - Neuropsychiatr Dis Treat (2015)

Bottom Line: Mini-mental state examination score significantly increased from baseline to end treatment (+3.19, P=0.002).Of note, behavioral disorders assessed through neuropsychiatric inventory significantly decreased (-28.78, P<0.001).This pilot study has shown EBS to be a promising, effective, and safe tool to treat cognitive impairment, in addition to the drugs presently available.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine and Medical Therapy, Section of Geriatrics, University of Pavia, Pavia, Italy ; Agency for Elderly People Services, Santa Margherita Hospital, Pavia, Italy ; Ambra Elektron, Italian Association of Biophysics for the Study of Electromagnetic Fields in Medicine, Turin, Italy.

ABSTRACT

Background and aims: In the last decade, the development of different methods of brain stimulation by electromagnetic fields (EMF) provides a promising therapeutic tool for subjects with impaired cognitive functions. Emisymmetric bilateral stimulation (EBS) is a novel and innovative EMF brain stimulation, whose working principle is to introduce very weak noise-like stimuli through EMF to trigger self-arrangements in the cortex of treated subjects, thereby improving cognitive faculties. The aim of this pilot study was to investigate in patients with cognitive impairment the effectiveness of EBS treatment with respect to global cognitive function, episodic memory, and executive functions.

Methods: Fourteen patients with cognitive decline (six with mild cognitive impairment and eight with Alzheimer's disease) underwent three EBS applications per week to both the cerebral cortex and auricular-specific sites for a total of 5 weeks. At baseline, after 2 weeks and 5 weeks, a neuropsychological assessment was performed through mini-mental state examination, free and cued selective reminding tests, and trail making test. As secondary outcomes, changes in behavior, functionality, and quality of life were also evaluated.

Results: After 5 weeks of standardized EBS therapy, significant improvements were observed in all neurocognitive assessments. Mini-mental state examination score significantly increased from baseline to end treatment (+3.19, P=0.002). Assessment of episodic memory showed an improvement both in immediate and delayed recalls (immediate recall =+7.57, P=0.003; delayed recall =+4.78, P<0.001). Executive functions significantly improved from baseline to end stimulation (trail making test A -53.35 seconds; P=0.001). Of note, behavioral disorders assessed through neuropsychiatric inventory significantly decreased (-28.78, P<0.001). The analysis concerning the Alzheimer's disease and mild cognitive impairment group confirmed a significant improvement of cognitive functions and behavior after EBS treatment.

Conclusion: This pilot study has shown EBS to be a promising, effective, and safe tool to treat cognitive impairment, in addition to the drugs presently available. Further investigations and controlled clinical trials are warranted.

No MeSH data available.


Related in: MedlinePlus

Individual values of primary outcomes during protocol treatment.Note: The black vertical lines in the figures separate the bars of the AD group from MCI group.Abbreviations: MMSE, mini–mental state examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581783&req=5

f2-ndt-11-2391: Individual values of primary outcomes during protocol treatment.Note: The black vertical lines in the figures separate the bars of the AD group from MCI group.Abbreviations: MMSE, mini–mental state examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment.

Mentions: Figure 2 shows all the individual values regarding the primary cognitive outcomes across weeks and divided into cognitive condition (AD and MCI patients).


An innovative intervention for the treatment of cognitive impairment-Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer's disease and mild cognitive impairment: an open-label study.

Guerriero F, Botarelli E, Mele G, Polo L, Zoncu D, Renati P, Sgarlata C, Rollone M, Ricevuti G, Maurizi N, Francis M, Rondanelli M, Perna S, Guido D, Mannu P - Neuropsychiatr Dis Treat (2015)

Individual values of primary outcomes during protocol treatment.Note: The black vertical lines in the figures separate the bars of the AD group from MCI group.Abbreviations: MMSE, mini–mental state examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581783&req=5

f2-ndt-11-2391: Individual values of primary outcomes during protocol treatment.Note: The black vertical lines in the figures separate the bars of the AD group from MCI group.Abbreviations: MMSE, mini–mental state examination; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
Mentions: Figure 2 shows all the individual values regarding the primary cognitive outcomes across weeks and divided into cognitive condition (AD and MCI patients).

Bottom Line: Mini-mental state examination score significantly increased from baseline to end treatment (+3.19, P=0.002).Of note, behavioral disorders assessed through neuropsychiatric inventory significantly decreased (-28.78, P<0.001).This pilot study has shown EBS to be a promising, effective, and safe tool to treat cognitive impairment, in addition to the drugs presently available.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine and Medical Therapy, Section of Geriatrics, University of Pavia, Pavia, Italy ; Agency for Elderly People Services, Santa Margherita Hospital, Pavia, Italy ; Ambra Elektron, Italian Association of Biophysics for the Study of Electromagnetic Fields in Medicine, Turin, Italy.

ABSTRACT

Background and aims: In the last decade, the development of different methods of brain stimulation by electromagnetic fields (EMF) provides a promising therapeutic tool for subjects with impaired cognitive functions. Emisymmetric bilateral stimulation (EBS) is a novel and innovative EMF brain stimulation, whose working principle is to introduce very weak noise-like stimuli through EMF to trigger self-arrangements in the cortex of treated subjects, thereby improving cognitive faculties. The aim of this pilot study was to investigate in patients with cognitive impairment the effectiveness of EBS treatment with respect to global cognitive function, episodic memory, and executive functions.

Methods: Fourteen patients with cognitive decline (six with mild cognitive impairment and eight with Alzheimer's disease) underwent three EBS applications per week to both the cerebral cortex and auricular-specific sites for a total of 5 weeks. At baseline, after 2 weeks and 5 weeks, a neuropsychological assessment was performed through mini-mental state examination, free and cued selective reminding tests, and trail making test. As secondary outcomes, changes in behavior, functionality, and quality of life were also evaluated.

Results: After 5 weeks of standardized EBS therapy, significant improvements were observed in all neurocognitive assessments. Mini-mental state examination score significantly increased from baseline to end treatment (+3.19, P=0.002). Assessment of episodic memory showed an improvement both in immediate and delayed recalls (immediate recall =+7.57, P=0.003; delayed recall =+4.78, P<0.001). Executive functions significantly improved from baseline to end stimulation (trail making test A -53.35 seconds; P=0.001). Of note, behavioral disorders assessed through neuropsychiatric inventory significantly decreased (-28.78, P<0.001). The analysis concerning the Alzheimer's disease and mild cognitive impairment group confirmed a significant improvement of cognitive functions and behavior after EBS treatment.

Conclusion: This pilot study has shown EBS to be a promising, effective, and safe tool to treat cognitive impairment, in addition to the drugs presently available. Further investigations and controlled clinical trials are warranted.

No MeSH data available.


Related in: MedlinePlus